Beginner's Guide to GLP-1 Medications

Last updated: March 10, 2026 — Reviewed by CompoundTalk Medical Advisory Board

1. What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists (GLP-1 RAs) are a class of injectable and oral medications that mimic the action of the naturally occurring hormone glucagon-like peptide-1. This hormone is secreted by L-cells in the small intestine in response to food intake and plays a central role in glucose homeostasis and appetite regulation [1].

Originally developed for the treatment of type 2 diabetes mellitus, several GLP-1 RAs have since received regulatory approval for chronic weight management in individuals with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity [2].

These medications have transformed the therapeutic landscape for obesity, with clinical trials demonstrating mean weight reductions of 15–22.5% of body weight—results previously achievable only through bariatric surgery [3].

2. How Do GLP-1 Medications Work?

Mechanism of Action

GLP-1 receptor agonists work through multiple interconnected physiological pathways:

• GLP-1 Receptor Binding: These medications bind to and activate the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed throughout the body, including the pancreas, brain, heart, gastrointestinal tract, and kidneys [4].
• The Incretin Effect: In the pancreas, GLP-1R activation stimulates glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells. This "incretin effect" accounts for approximately 50–70% of total insulin secretion after an oral glucose load [5].
• Central Appetite Regulation: GLP-1 RAs cross the blood-brain barrier and act on receptors in the hypothalamus and brainstem (particularly the nucleus tractus solitarius and area postrema), reducing appetite and increasing satiety signaling [6].
• Gastric Emptying: These agents slow the rate at which food leaves the stomach (delayed gastric emptying), contributing to prolonged feelings of fullness after meals [7].
• Food Reward Pathways: Emerging evidence suggests GLP-1 RAs modulate mesolimbic dopamine signaling, reducing the hedonic drive to eat and diminishing cravings for high-calorie foods [8].

Dual and Triple Agonists

Newer agents such as tirzepatide act on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing greater effects on insulin sensitivity and weight loss than GLP-1-selective agents [9]. Investigational agents like retatrutide are triple agonists, targeting GLP-1, GIP, and glucagon receptors simultaneously, with phase 2 trial data showing up to 24.2% mean body weight reduction at 48 weeks [10].

3. Available Medications

SC = subcutaneous; T2DM = type 2 diabetes mellitus; GLP-1R = GLP-1 receptor; GIPR = GIP receptor; GCGR = glucagon receptor.

4. Dosing Basics

All GLP-1 receptor agonists follow a dose-escalation (titration) schedule designed to minimize gastrointestinal side effects. Starting at the lowest dose and gradually increasing allows your body to adapt to the medication.

Semaglutide (Wegovy) Titration

Tirzepatide (Zepbound) Titration

5. Common Side Effects

The most frequently reported side effects of GLP-1 receptor agonists are gastrointestinal in nature and tend to be most pronounced during dose escalation. Most side effects are mild to moderate and diminish over time [11].

• Nausea — Reported in 30–44% of patients; typically most severe in the first 1–2 weeks after each dose increase
• Diarrhea — Reported in 15–30% of patients; usually transient
• Constipation — Reported in 10–24% of patients; due to slowed gastric emptying
• Vomiting — Reported in 6–25% of patients; eating smaller meals can help
• Injection site reactions — Mild redness, swelling, or itching at injection site (3–6%)
• Fatigue — Reported in 5–11% of patients, often related to reduced caloric intake
• Headache — Reported in 10–14% of patients, typically early in treatment

For a comprehensive side effects guide including management strategies, see our Side Effects Guide.

6. What to Expect: Week-by-Week Timeline

Weeks 1–2: Initiation Phase

You are at the lowest dose. Most people notice a decrease in appetite within the first few days. Some experience mild nausea, which typically subsides within 3–5 days. Weight loss at this stage is usually modest (1–3 lbs), though some of this may be water weight from reduced carbohydrate and sodium intake.

Weeks 3–4: Adjustment

Your body continues adapting to the medication. Appetite suppression becomes more consistent. You may notice you feel full sooner during meals and have reduced interest in snacking between meals. Any initial GI side effects typically resolve.

Weeks 5–8: First Dose Increase

After your first dose escalation, expect a brief return of mild GI symptoms as your body adjusts to the higher dose. Weight loss usually becomes more noticeable at this stage, with most patients reporting 3–5% of body weight lost by week 8 [12].

Weeks 9–16: Continued Titration

As you continue to titrate upward, weight loss accelerates. Many patients report significant changes in food preferences, with reduced cravings for high-calorie foods. Blood glucose levels (if elevated at baseline) typically show marked improvement. You should be having regular follow-ups with your prescriber during this period.

Months 4–6: Approaching Maintenance

By this stage, most patients reach or are nearing their maintenance dose. Average weight loss of 10–15% of body weight is typical for semaglutide 2.4 mg, and 15–22% for tirzepatide at maximum doses. GI side effects should be minimal. Your prescriber may order labs to check metabolic parameters [13].

Months 6–12+: Maintenance Phase

Weight loss typically continues for 12–18 months before plateauing. Ongoing use is generally recommended to maintain weight loss, as discontinuation is associated with regain of approximately two-thirds of lost weight within one year [14]. Focus during this phase should include:

• Adequate protein intake (1.0–1.2 g/kg/day minimum) to preserve lean mass
• Regular resistance training
• Monitoring for nutritional deficiencies
• Regular follow-up with your healthcare provider

7. When to See a Doctor

You should also contact your prescriber if you experience side effects that do not resolve after 1–2 weeks at a given dose, if you are losing weight too rapidly (more than 1% body weight per week after the initial period), or if you have questions about dose adjustments [15].

8. Practical Tips for Success

• Inject on the same day each week at roughly the same time. Set a phone reminder.
• Rotate injection sites between abdomen, thigh, and upper arm. Keep a log.
• Eat slowly and stop when satisfied. Overeating on GLP-1 medications frequently triggers nausea.
• Stay hydrated. Aim for at least 64 oz of water daily; more if you are experiencing GI side effects.
• Prioritize protein. Aim for 25–30 grams per meal to preserve muscle mass during weight loss.
• Start or continue exercise. A combination of resistance training and moderate cardio is ideal.
• Track your progress with weekly weigh-ins, measurements, or photos—but avoid daily scale obsession.
• Join our community. The CompoundTalk forums have thousands of members sharing their experiences.

9. Frequently Asked Questions

For an extensive list of common questions and science-based answers, visit our FAQ page.

10. Further Reading

• Dosing Calculator & Titration Reference
• Comprehensive Side Effects Guide
• How to Read a Certificate of Analysis (COA)
• Insurance Coverage & Savings Guide